Evaluation of the state of active ingredients in pharmaceutical preparations using fourier transform-Raman difference spectra.
To examine the pharmaceutical application of Fourier transform (FT)-Raman spectroscopy, the state of active pharmaceutical ingredients (APIs) in a preparation of several forms was evaluated by investigating the Raman difference spectra between the preparation and excipient. The difference spectra indicated that APIs in alacepril tablets, caffeine sustained-release granules, and quinidine sulfate granules remained unchanged after the manufacturing process. However, the state of sparfloxacin in nanoparticles changed, although it remained unchanged in tablets or powders. These results show that the FT-Raman difference spectrum is expected to be utilized in the field of quality control of crystalline pharmaceutical preparations.
Mifune
Masaki
M
Department of Pharmaceutical Sciences, Graduate School of Medicine and Dentistry and Pharmaceutical Sciences, Okayama University, Japan. mifune@pharm.okayama-u.ac.jp
Iwasaki
Toshinobu
T
Kozaki
Yukari
Y
Tsukamoto
Ikuko
I
Saito
Madoka
M
Kitamura
Youji
Y
Yamaguchi
Toshikazu
T
Saito
Yutaka
Y
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000737:chemistry; D000995:Antitubercular Agents / Q000737:chemistry; D002216:Captopril / Q000031:analogs & derivatives / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003460:Crystallization; D003692:Delayed-Action Preparations; D024841:Fluoroquinolones / Q000737:chemistry*; D053758:Nanoparticles; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011208:Powders; D011786:Quality Control; D017550:Spectroscopy, Fourier Transform Infrared; D013607:Tablets
D000806:Angiotensin-Converting Enzyme Inhibitors; D000995:Antitubercular Agents; D003692:Delayed-Action Preparations; D024841:Fluoroquinolones; D004364:Pharmaceutical Preparations; D011208:Powders; D013607:Tablets; D002216:Captopril; C061363:sparfloxacin; C046835:alacepril